Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT06466785
- Locations
- 🇬🇪
Batumi Dialysis and Nephrology Center, Batumi, Georgia
🇬🇪L.Managadze National Center of Urology, Tbilisi, Georgia
🇬🇪Tbilisi Heart And Vascular Clinic, Tbilisi, Georgia
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Yi Fang
- Target Recruit Count
- 74
- Registration Number
- NCT05864261
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 312
- Registration Number
- NCT05768997
- Locations
- 🇰🇷
Hallym University Medical Center, Anyang-si, Korea, Republic of
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
- Conditions
- Iron-deficiencyPrematurityIron MalabsorptionIron Deficiency Anemia
- Interventions
- Drug: Oral iron supplementsDrug: Low Molecular Weight Iron Dextran
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 120
- Registration Number
- NCT05340465
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
- Conditions
- Renal Anemia
- Interventions
- Drug: AND017 capsules TIWDrug: AND017 capsules QW
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 175
- Registration Number
- NCT05265325
- Locations
- 🇺🇸
North America Research Institute, Riverside, California, United States
🇺🇸US Renal Care - Pine Bluff, Pine Bluff, Arkansas, United States
🇨🇳The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China
Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Rufaida Mazahir
- Target Recruit Count
- 50
- Registration Number
- NCT04959578
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 13
- Registration Number
- NCT04798339
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory-Winship Cancer Institute, Atlanta, Georgia, United States
Darbepoetin in Neonatal Encephalopathy Trial
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 150
- Registration Number
- NCT04432662
- Locations
- 🇬🇧
Birmingham Womens Hospital, Birmingham, United Kingdom
🇬🇧Imperial College Healthcare Trust, London, United Kingdom
🇬🇧Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 319
- Registration Number
- NCT04313153
- Locations
- 🇪🇸
Research Site, Valencia, Spain
🇪🇸Research Site #2, Barcelona, Spain
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 172
- Registration Number
- NCT04027517
- Locations
- 🇰🇷
SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.